On the use of liposome controls in studies investigating the clinical potential of extracellular vesicle-based drug delivery systems - A commentary.
暂无分享,去创建一个
Meg Duroux | Thomas Lars Andresen | Johann Mar Gudbergsson | Jens Bæk Simonsen | Kasper Bendix Johnsen | T. Andresen | J. Simonsen | M. Duroux | Torben Moos | T. Moos | K. B. Johnsen | J. M. Gudbergsson
[1] Gary K. Schwartz,et al. Tumour exosome integrins determine organotropic metastasis , 2015, Nature.
[2] John W. Park. Liposome-based drug delivery in breast cancer treatment , 2002, Breast Cancer Research.
[3] Andrew Z. Wang,et al. EPR or no EPR? The billion-dollar question , 2015, Science Translational Medicine.
[4] H M Patel,et al. Serum opsonins and phagocytosis of saturated and unsaturated phospholipid liposomes. , 1989, Biochimica et biophysica acta.
[5] L. O’Driscoll,et al. Biological properties of extracellular vesicles and their physiological functions , 2015, Journal of extracellular vesicles.
[6] Andreas Kjær,et al. Positron Emission Tomography Based Elucidation of the Enhanced Permeability and Retention Effect in Dogs with Cancer Using Copper-64 Liposomes. , 2015, ACS nano.
[7] Theresa M Allen,et al. Advantages of liposomal delivery systems for anthracyclines. , 2004, Seminars in oncology.
[8] Raghu Kalluri,et al. Exosomes Facilitate Therapeutic Targeting of Oncogenic Kras in Pancreatic Cancer , 2017, Nature.
[9] Meg Duroux,et al. A comprehensive overview of exosomes as drug delivery vehicles - endogenous nanocarriers for targeted cancer therapy. , 2014, Biochimica et biophysica acta.
[10] M. Komiyama,et al. Chemistry Can Make Strict and Fuzzy Controls for Bio-Systems: DNA Nanoarchitectonics and Cell-Macromolecular Nanoarchitectonics , 2017 .
[11] C. Benz,et al. Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine , 2009, Cancer Chemotherapy and Pharmacology.
[12] T. Anchordoquy,et al. Biodistribution and delivery efficiency of unmodified tumor-derived exosomes. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[13] T. Moos,et al. Revisiting nanoparticle technology for blood-brain barrier transport: Unfolding at the endothelial gate improves the fate of transferrin receptor-targeted liposomes. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[14] J. Gubernator,et al. Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased in vivo activity , 2011, Expert opinion on drug delivery.
[15] I. Toth,et al. Recent advances in self‐assembled peptides: Implications for targeted drug delivery and vaccine engineering , 2017, Advanced drug delivery reviews.
[16] Yuki Takahashi,et al. Visualization and in vivo tracking of the exosomes of murine melanoma B16-BL6 cells in mice after intravenous injection. , 2013, Journal of biotechnology.
[17] Koen Raemdonck,et al. Therapeutic and diagnostic applications of extracellular vesicles. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[18] Maria Ericsson,et al. Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter. , 2014, ACS nano.
[19] T. Andresen,et al. Targeting transferrin receptors at the blood-brain barrier improves the uptake of immunoliposomes and subsequent cargo transport into the brain parenchyma , 2017, Scientific Reports.
[20] J. Kjems,et al. DNA nanovehicles and the biological barriers. , 2016, Advanced drug delivery reviews.
[21] S M Moghimi,et al. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. , 2012, Annual review of pharmacology and toxicology.
[22] Molly M Stevens,et al. Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[23] Juliane Nguyen,et al. Exosomes as therapeutics: The implications of molecular composition and exosomal heterogeneity. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[24] F. Dosio,et al. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential , 2006, International journal of nanomedicine.
[25] Tianzhi Yang,et al. Exosome Delivered Anticancer Drugs Across the Blood-Brain Barrier for Brain Cancer Therapy in Danio Rerio , 2014, Pharmaceutical Research.
[26] P. Cullis,et al. Liposomal drug delivery systems: from concept to clinical applications. , 2013, Advanced drug delivery reviews.
[27] T. Andresen,et al. Remote Loading of (64)Cu(2+) into Liposomes without the Use of Ion Transport Enhancers. , 2015, ACS applied materials & interfaces.
[28] R. Vandenbroucke,et al. Comparing exosome-like vesicles with liposomes for the functional cellular delivery of small RNAs. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[29] Meg Duroux,et al. Systematic review of factors influencing extracellular vesicle yield from cell cultures , 2016, Cytotechnology.
[30] D. Hallahan,et al. Tumor-targeted delivery of liposome-encapsulated doxorubicin by use of a peptide that selectively binds to irradiated tumors. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[31] M. Chopp,et al. Systemic administration of cell-free exosomes generated by human bone marrow derived mesenchymal stem cells cultured under 2D and 3D conditions improves functional recovery in rats after traumatic brain injury , 2017, Neurochemistry International.
[32] Samuel A Wickline,et al. Maximizing exosome colloidal stability following electroporation. , 2014, Analytical biochemistry.
[33] Wim E Hennink,et al. Cancer nanomedicines: oversold or underappreciated? , 2017, Expert opinion on drug delivery.
[34] Imre Mäger,et al. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting , 2015, Journal of extracellular vesicles.
[35] R. Schiffelers,et al. PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[36] Thomas L Andresen,et al. Liposomal cancer therapy: exploiting tumor characteristics , 2010, Expert opinion on drug delivery.
[37] Michelle E. Hung,et al. Stabilization of Exosome-targeting Peptides via Engineered Glycosylation* , 2015, The Journal of Biological Chemistry.
[38] P. Cullis,et al. Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. , 1992, The Journal of biological chemistry.
[39] C. Théry,et al. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes , 2016, Proceedings of the National Academy of Sciences.
[40] Jaesung Park,et al. Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors. , 2013, ACS nano.
[41] S. Moghimi,et al. Differential properties of organ-specific serum opsonins for liver and spleen macrophages. , 1989, Biochimica et biophysica acta.
[42] Thomas D. Schmittgen,et al. Achieving the Promise of Therapeutic Extracellular Vesicles: The Devil is in Details of Therapeutic Loading , 2017, Pharmaceutical Research.
[43] M. Zöller,et al. Toward tailored exosomes: the exosomal tetraspanin web contributes to target cell selection. , 2012, The international journal of biochemistry & cell biology.
[44] L. Gurevich,et al. Evaluation of electroporation-induced adverse effects on adipose-derived stem cell exosomes , 2016, Cytotechnology.
[45] Thomas D. Schmittgen,et al. Low active loading of cargo into engineered extracellular vesicles results in inefficient miRNA mimic delivery , 2017, Journal of extracellular vesicles.
[46] Fabian Kiessling,et al. Cancer nanomedicine: Is targeting our target? , 2016, Nature reviews. Materials.
[47] P. Kantoff,et al. Cancer nanomedicine: progress, challenges and opportunities , 2016, Nature Reviews Cancer.
[48] M. Zöller,et al. Exosome target cell selection and the importance of exosomal tetraspanins: a hypothesis. , 2011, Biochemical Society transactions.
[49] Ulrik B Nielsen,et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[50] K. Braeckmans,et al. Electroporation-induced siRNA precipitation obscures the efficiency of siRNA loading into extracellular vesicles. , 2013, Journal of controlled release : official journal of the Controlled Release Society.
[51] A. J. Tavares,et al. Analysis of nanoparticle delivery to tumours , 2016 .
[52] Yechezkel Barenholz,et al. Pharmacokinetics of Pegylated Liposomal Doxorubicin , 2003, Clinical pharmacokinetics.
[53] J. Redzic,et al. Examination of the specificity of tumor cell derived exosomes with tumor cells in vitro. , 2014, Biochimica et biophysica acta.
[54] M. Wood,et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes , 2011, Nature Biotechnology.
[55] J. Simonsen. What Are We Looking At? Extracellular Vesicles, Lipoproteins, or Both? , 2017, Circulation research.